Global RNA Therapeutics Market Analysis Report 2022: Future Growth Potential Driven by Co-Development Programs and Robust Clinical Trials for Diverse Disease Areas
20 juin 2022 08h03 HE
|
Research and Markets
Dublin, June 20, 2022 (GLOBE NEWSWIRE) -- The "Global RNA Therapeutics Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This research service provides an overview...
NorthX Biologics utser branschveteraner till sin styrelse
14 juin 2022 02h00 HE
|
NorthX Biologics Matfors AB
MATFORS, Sverige, June 14, 2022 (GLOBE NEWSWIRE) -- Sverigebaserade NorthX Biologics ("NorthX"), som specialiserar sig på processutveckling och GMP-tillverkning av avancerade biologiska läkemedel,...
NorthX Biologics appoints industry veterans to its board of directors
14 juin 2022 02h00 HE
|
NorthX Biologics Matfors AB
MATFORS, Sweden, June 14, 2022 (GLOBE NEWSWIRE) -- Sweden-based NorthX Biologics (“NorthX”), which focuses on process development and GMP manufacture of advanced biological drugs, has announced the...
Outlook on the RNA Based Therapeutic Global Market to 2030 - Multifactorial Disease Targeting Presents Opportunities
28 avr. 2022 06h43 HE
|
Research and Markets
Dublin, April 28, 2022 (GLOBE NEWSWIRE) -- The "RNA Based Therapeutic Market by Disease Type, Application and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been...
Global Capillary Electrophoresis Market Report 2022-2031: Opportunities with Government and Private Support for Capillary Electrophoresis on a Large Scale
28 avr. 2022 04h38 HE
|
Research and Markets
Dublin, April 28, 2022 (GLOBE NEWSWIRE) -- The "Capillary Electrophoresis Market - A Global and Regional Analysis: Focus on Product Type, Mode, Application, End User - Analysis and Forecast,...
Pfizer und BioNTech veröffentlichen Daten zu starker Immunantwort nach Auffrischungsimpfung mit dem COVID-19-Impfstoff bei Kindern im Alter von 5 bis 11 Jahren
14 avr. 2022 06h45 HE
|
BioNTech SE
Daten einer Subanalyse mit 30 Seren aus einer klinischen Phase-2/3-Studie mit Kindern im Alter von 5 bis 11 Jahren zeigen einen 36-fachen Anstieg der neutralisierenden Antikörpertiter gegen die...
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
14 avr. 2022 06h45 HE
|
BioNTech SE
Data from a subanalysis of 30 sera from a Phase 2/3 clinical trial of children 5 through 11 years of age show a 36-fold increase in SARS-CoV-2 Omicron neutralizing titers following a booster (third)...
Global $47+ Billion mRNA Cancer Vaccines and Therapeutics Market is Expected to Grow at a CAGR of over 17.10% During 2022-2028 Vantage Market Research
05 avr. 2022 07h20 HE
|
Vantage Market Research
WASHINGTON, April 05, 2022 (GLOBE NEWSWIRE) -- The Global mRNA Cancer Vaccines and Therapeutics Market finds that increasing prevalence of cancer across the globe is expediting market growth. The...
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
15 mars 2022 18h00 HE
|
BioNTech SE
Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who...
BioNTech und Regeneron erweitern strategische Zusammenarbeit zur klinischen Entwicklung von FixVac und Libtayo® (Cemiplimab) Kombination gegen nicht-kleinzelliges Lungenkarzinom
08 mars 2022 08h27 HE
|
BioNTech SE
BioNTech und Regeneron planen die gemeinsame Durchführung klinischer Studien zur Untersuchung des FixVac-Kandidaten BNT116 in Kombination mit Libtayo zur Behandlung von fortgeschrittenem...